roxadustat
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia
Conditions
Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia
Trial Timeline
Jun 22, 2016 → Aug 2, 2017
NCT ID
NCT02780726About roxadustat
roxadustat is a phase 3 stage product being developed by Astellas Pharma for Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02780726. Target conditions include Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia.
What happened to similar drugs?
3 of 6 similar drugs in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia were approved
Approved (3) Terminated (1) Active (3)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05970172 | Phase 3 | Recruiting |
| NCT04408820 | Pre-clinical | Completed |
| NCT04076943 | Phase 2 | Completed |
| NCT03960489 | Phase 1 | Completed |
| NCT02964936 | Phase 3 | Completed |
| NCT02965040 | Phase 1 | Completed |
| NCT02780726 | Phase 3 | Completed |
| NCT02780141 | Phase 3 | Completed |
| NCT02779764 | Phase 3 | Completed |
| NCT01630889 | Phase 2 | Completed |
| NCT01244763 | Phase 2 | Completed |
| NCT01083888 | Phase 1 | Completed |
Competing Products
20 competing products in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia